Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 68 of 6351
-
Gene therapy hope for babies with rare muscle disease
Disease control Recruiting nowGB221 is a gene therapy that delivers a working SMN1 gene to the motor neurons of people with spinal muscular atrophy (SMA) Type 1. This study will evaluate the safety, tolerability and efficacy of GB221 in two groups: 1. participants aged from 2 weeks to younger than 12 months …
Phase 1/2 • Sponsor: Gemma Biotherapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Off-the-Shelf CAR-T cells take on tough blood cancers
Disease control Recruiting nowThis study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, which can save time and reduce costs. It ta…
Phase 1/2 • Sponsor: AvenCell Therapeutics, Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo aims to turn Chemo-Resistant breast cancer curable
Disease control Recruiting nowThe goal of this clinical trial is to test whether a "rescue" strategy can turn chemotherapy-resistant triple-negative breast cancer (TNBC) into a curable state. Patients whose tumors fail to shrink after 2 cycles of standard neoadjuvant chemotherapy will receive a short, high-pr…
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for Hard-to-Treat myeloma: phase 3 trial launches
Disease control Recruiting nowThis study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising new combo therapy targets hard-to-treat lymphoma
Disease control OngoingThis study aims to evaluate the efficacy and safety of tafasitamab combined with lenalidomide plus standard immunochemotherapy, followed by sequential autologous stem cell transplantation (ASCT), in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising ALS drug enters final testing phase
Disease control Not yet recruitingThe objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Phase 3 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental therapy offers hope for kids with Tough-to-Treat leukemia
Disease control Recruiting nowA Phase 1 clinical trial to evaluate the safety and early efficacy of Chimeric Antigen Receptor T-cell (CAR T-cell) with IL-7Rα signaling targeting CD19 in children with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (ALL) after complete standard treatments.
Phase 1 • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New CAR-T therapy aims to keep High-Risk leukemia in remission
Disease control Recruiting nowThis single-center, open-label, single-arm, prospective study will evaluate the safety, tolerability, and efficacy of CD22/CD19 dual-target chimeric antigen receptor T-cell (CAR-T) therapy as consolidation treatment in patients with high-risk B-cell acute lymphoblastic leukemia (…
Phase 1/2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Radioactive antibody could boost stem cell transplant success in tough leukemia
Disease control Not yet recruitingThis is a multicenter, open-label study in people aged 18 and older with relapsed or refractory acute myeloid leukemia. It has two parts. In Phase 2, we are testing three radiation dose levels of 131I-apamistamab combined with fludarabine and low-dose whole-body radiation before …
Phase 2/3 • Sponsor: Actinium Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 16:44 UTC
-
New RSV prevention strategy for infants under study in bogotá
Prevention OngoingThis study aims to evaluate the real-world effectiveness of two preventive immunization strategies against Respiratory Syncytial Virus (RSV)-associated severe acute respiratory infection in infants less than six months of age in Bogotá, Colombia. The strategies include maternal v…
Sponsor: Bogotá District Health Secretariat • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
New cocktail of drugs aims to fight advanced stomach cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Aden…
Phase 3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Not yet recruitingThis is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19-IL-15/IL15sushi cCAR T cells in patients with relapsed and/or refractory SLE, with or without Lupus Nephritis.
Phase 1/2 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous CD19-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
Phase 1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Stroke-Clot zapper: new device could save brains within 24 hours
Disease control Not yet recruitingSupernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours of symptom onset or from last known well time.
Sponsor: Gravity Medical Technology, INC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Lab-grown heart cells injected into failing hearts: a new hope?
Disease control Not yet recruitingThe purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.
Phase 1/2 • Sponsor: Heartseed Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New combo therapy aims to stop oral cancer from coming back
Disease control Recruiting nowThis is a multicenter, open-label, randomized phase III clinical trial evaluating perioperative treatment with sintilimab combined with chemotherapy in patients with locally advanced oral squamous cell carcinoma. Despite standard treatment with surgery followed by postoperative …
Phase 3 • Sponsor: Qunxing Li,MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Zipper therapy breakthrough: new combo may boost recovery in rare brain disease
Disease control Recruiting nowStudy Title: A National, Multicenter, Randomized Controlled Trial of the Modified Zipper Therapy in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (ELITE Study) Brief Summary: The goal of this clinical trial is to evaluate the efficacy and safety of a novel seque…
Phase 3 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New pill takes on hard-to-treat lung cancer in major trial
Disease control Not yet recruitingThis is a multicenter, randomized, open-label, phase 3 clinical trial designed to evaluate the efficacy and safety of JMKX001899 compared to docetaxel in patients with previously treated, KRAS G12C-mutant advanced or metastatic non-small cell lung cancer (NSCLC). KRAS G12C mutat…
Phase 3 • Sponsor: Jemincare • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New obesity drug aims to beat semaglutide in major trial
Disease control Recruiting nowThe primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
Phase 3 • Sponsor: Kailera • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for ovarian cancer: experimental drug AZD5335 faces off against standard care
Disease control Recruiting nowThe intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα l…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC